Evidence map›Paper›PMID 34702772›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2022

Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.

Yue Cao, Catherine T Haring, Collin Brummel, Chandan Bhambhani, Madhava Aryal, Choonik Lee, Molly Heft Neal, Apurva Bhangale, Wenjin Gu, Keith Casper and 15 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 7 pooled it
5.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 7 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial ofInternational journal of radiation oncology, biology, physics · 2023
    Trial
  10. Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Liquid Biopsies and Molecular Imaging for Precise Cancer Management.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

Yue Cao *Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Catherine T Haring *Department of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Collin BrummelDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Chandan BhambhaniDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Madhava AryalDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Choonik LeeDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Molly Heft NealDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Apurva BhangaleDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Wenjin GuDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-0028-1645
Keith CasperDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Kelly MalloyDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Yilun SunDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-1341-382X
Andrew ShumanDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Mark E PrinceDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Matthew E SpectorDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Steven ChinnDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Jennifer ShahDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Caitlin SchonewolfDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Jonathan B McHughRogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Ryan E MillsDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-3425-6998
Muneesh TewariDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Francis P WordenDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Paul L SwiecickiDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-2286-3555
Michelle Mierzwa *Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. mmierzwa@umich.edu.
J Chad Brenner *Department of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-3238-1111
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Functional imaging-directed adaptive therapy of head and neck cancerR01CA184153 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CAO, YUE · 2015 to 2019
$2.4M
Quantitative MRI models of HN Cancers for Physiological Adaption of RTU01CA183848 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CAO, YUE · 2014 to 2019
$2.0M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA184153NCI NIH HHS U01 CA183848
6 · The paper itself

Abstract

purposeIn locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC), (i) to investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and association with tumor progression after chemoradiation, and (ii) to compare the predictive value of ctDNA to imaging biomarkers of MRI and FDG-PET. EXPERIMENTAL

designSerial blood samples were collected from patients with AJCC8 stage III OPSCC (

resultsLow pretreatment ctDNA and an early increase in ctDNA at week 2 compared with baseline were significantly associated with superior FFP (

conclusionsEarly ctDNA kinetics during definitive chemoradiation may predict therapy response in stage III OPSCC.

Indexed as

AlphapapillomavirusCarcinoma, Squamous CellCirculating Tumor DNAHead and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsBiomarkersFluorodeoxyglucose F18HumansKineticsPapillomaviridaePrognosisRetrospective StudiesSquamous Cell Carcinoma of Head and NeckBiomarkersCirculating Tumor DNAFluorodeoxyglucose F18

Identifiers

PMID34702772
PMCPMC8785355
OpenAlexW3211020881

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.